Page 180 - Eceptor News Today

A new study has been published in Frontiers in Immunology, where scientists developed a universal SARS-CoV-2 neutralizing antibody, MG1141A.

In a new study, researchers developed a bioinformatics pipeline that uses RNA sequencing data to identify altered genes and signaling pathways affected by viral infection.

A new study shows that the ACE2 and RBD of coronavirus spike fragments have different binding strengths and dissociation rates when they are glycosylated and non-glycosylated.

Combining two agents to block a parasitic worm's life cycle boosted survival from a potentially deadly tropical disease to 85% in animal models, far better than either treatment alone, according to a proof-of-concept study led by UT Southwestern Medical Center pharmacologists.

As any parent knows, infants are prone to getting respiratory infections.

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care investigated whether nivolumab has an added benefit over watchful waiting in the adjuvant treatment of adults with carcinoma of the esophagus or the gastroesophageal junction and pathological residual disease after prior neoadjuvant chemoradiotherapy (CRT).

Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma.

A new study discusses the effect of the Omicron variant’s mutations on its binding efficiency to the ACE2 receptor.

A University of Florida Health researcher has successfully analyzed the many mutations in the omicron variant of the SARS-CoV-2 virus, a crucial step in better understanding the variant's potential threat and ways to combat it.

A recent study tested the RBD of 2 sarbecoviruses found in Russian horseshoe bats and other clades 3 viruses for their ability to invade the human cell.